Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.72 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.67 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.67 |
| ▸ | CA2 | P00918 | 3/20 | 0.66 |
| ▸ | CA9 | Q16790 | 3/20 | 0.66 |
| ▸ | CA1 | P00915 | 2/20 | 0.66 |
| ▸ | CA4 | P22748 | 1/20 | 0.66 |
| ▸ | CA7 | P43166 | 1/20 | 0.66 |
| ▸ | CA12 | O43570 | 2/20 | 0.66 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2068526 | 0.89 | LMNA (0.82) | LMNAALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL11785265 | 0.85 | LMNA (0.77) | LMNAALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL4417172 | 0.85 | ALDH1A1 (0.65) | LMNAALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL4623054 | 0.84 | ALDH1A1 (0.75) | LMNAALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL8993697 | 0.83 | ALDH1A1 (0.78) | LMNAALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL3411259 | 0.82 | LMNA (0.72) | LMNAALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL8993799 | 0.81 | ALDH1A1 (0.76) | LMNAALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL2068110 | 0.81 | LMNA (0.70) | LMNAALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL4376657 | 0.81 | LMNA (0.70) | LMNAALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL9903086 | 0.81 | LMNA (0.70) | LMNAALDH1A1CYP2C9CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2020-05-12 | — | — | US | claimed |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2019-08-08 | — | — | US | claimed |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2018-10-09 | — | — | US | claimed |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2017-02-09 | — | — | US | claimed |
| US-8916585-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2014-12-23 | — | — | US | claimed |
| US-20130178417-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2013-07-11 | — | — | US | claimed |
| US-8017625-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2011-09-13 | — | — | US | claimed |
| EP-1644336-B1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN INC (US) | 2011-01-19 | — | — | EP | claimed |
| US-7863292-B2 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | FIBROGEN, INC. (US) | 2011-01-04 | — | — | US | claimed |
| US-7629357-B2 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. (US) | 2009-12-08 | — | — | US | claimed |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | FIBROGEN, INC. | 2008-11-27 | — | — | US | claimed |
| US-7323475-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2008-01-29 | — | — | US | claimed |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | FIBROGEN, INC. | 2007-08-09 | — | — | US | claimed |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. | 2007-07-05 | — | — | US | claimed |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | FIBROGEN, INC. | 2006-09-28 | — | — | US | claimed |
| EP-1644336-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2006-04-12 | — | — | EP | claimed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | claimed |
| WO-2004108681-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND THEIR USE IN INCREASING ENDOGENOUS ERYTHROPOIETIN | FIBROGEN, INC. (US) | 2004-12-16 | — | — | WO | claimed |
| US-11229637-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | FIBROGEN, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | FIBROGEN, INC. | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229637-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | LMNA 2670/4885ALDH1A1 1476/4885CYP2C9 3959/4885 |
| US-20130178417-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | LMNA 3562/4885ALDH1A1 1908/4885CYP2C9 4384/4885 |
| US-20080293763-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | LMNA 3562/4885ALDH1A1 1908/4885CYP2C9 4384/4885 |
| US-20170035747-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | LMNA 3562/4885ALDH1A1 1908/4885CYP2C9 4384/4885 |
| US-10646482-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | LMNA 2670/4885ALDH1A1 1476/4885CYP2C9 3959/4885 |
| US-20190240213-A1 | NOVEL NITROGEN-CONTAINING HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | HIF1AN, EGLN3, EGLN2 | LMNA 3562/4885ALDH1A1 1908/4885CYP2C9 4384/4885 |
| US-10092558-B2 | Nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, HIF1A, EGLN2 | LMNA 2670/4885ALDH1A1 1476/4885CYP2C9 3959/4885 |
| US-20070155784-A1 | Novel nitrogen-containing heteroaryl compounds and methods of use thereof | HIF1AN, EGLN3, EGLN2 | LMNA 3562/4885ALDH1A1 1908/4885CYP2C9 4384/4885 |
| US-20040254215-A1 | Adjust concentration of erythropoietin in blood; strokes; antiepileptic agents; liver disorders; antiulcer agents; central nervous system disorders | EPOR, HIF1AN, HIF1A | LMNA 1542/4885ALDH1A1 1829/4885CYP2C9 1173/4885 |
| US-20070185159-A1 | modulators of hypoxia inducible factors and/or endogenous erythropoietin, such as 1-Chloro-4-hydroxy-7-isopropoxy-isoquinoline-3-carboxylic acid (2-hydroxy-1-hydroxymethyl-ethyl)-amide, used for the treatment of anemic disorders, neurological disorders and/or injuries | HIF1AN, HIF1A, EPOR | LMNA 2338/4885ALDH1A1 389/4885CYP2C9 4573/4885 |
| US-20060217416-A1 | Antihypoxic agents; adjust concentration of erythropoietin concentration in blood; strokes; antiepileptic agents; neurodegenerative disease ; liver disorders; antiischemic agents | EPOR, HIF1AN, HIF1A | LMNA 2349/4885ALDH1A1 946/4885CYP2C9 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.